is xigduo a glp-1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Battle of GLP-1 delivery technologies

Historically, no, but qualifying Medicare beneficiaries can get coverage for Wegovy from July 1, 2026, until December 31, 2027, via the new Medicare GLP-1 Bridge program

It is important to note that individual responses vary, and outcomes depend on dosage titration, baseline metabolic status, and adherence to clinical protocols

See our full semaglutide versus tirzepatide comparison for additional context on the incretin therapy landscape

Advertisement I think what youre going to start seeing is new products being introduced to the market that actually have less of those side effects, which then would be more advantageous for athletes, said Matthew Fedoruk, the chief science officer at the U.S